Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs

Schizophrenia Research

Volumn 94, Issue 1-3, 2007, Pages 45-49

  Caspi, Asaf ^a,b   Reichenberg, Abraham ^c,d   Weiser, Mark ^a,b,e   Rabinowitz, Jonathan ^f   Shmushkevich, Motti ^e   Lubin, Gad ^e   Nahon, Daniella ^g   Vishne, Tali ^h   Davidson, Michael ^a,b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e MEDICAL CORPS   (Israel)

^f BAR ILAN UNIVERSITY   (Israel)

^g MINISTRY OF HEALTH   (Israel)

^h BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; EDUCATION; FEMALE; HUMAN; INTELLECT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGISTER; SCHIZOPHRENIA; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION DISORDERS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; REGISTRIES; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 34447106388     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.04.007     Document Type: Article

References (19)

1. Bailer J., Brauer W., and Rey E.R. Premorbid adjustment as predictor of outcome in schizophrenia: results of a prospective study. Acta Psychiatr. Scand. 93 5 (1996) 368-377
2. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., and Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 16 4 (1990) 551-561
3. Caspi A.E.A. Treatment-refractory schizophrenia. Dialogues Clin. Neurosci. 6 (2004) 61-70
4. Davidson M., Reichenberg A., Rabinowitz J., Weiser M., Kaplan Z., and Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am. J. Psychiatry 156 (1999) 1328-1335
5. Davis J.M., Schaffer C.B., Killian G.A., Kinard C., and Chan C. Important issues in the drug treatment of schizophrenia. Schizophr. Bull. 6 1 (1980) 70-87
6. Findling R.L., Jayathilake K., and Meltzer H.Y. Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia. Psychol. Med. 26 5 (1996) 1033-1041 (Sep.)
7. Gal R. The selection, classification and placement process. A Portrait of the Israeli Soldier (1986), Greenwood Press 77-96
8. Kane J., et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 9 (1988) 789-796
9. Keefe R.S., Mohs R.C., Losonczy M.F., Davidson M., Silverman J.M., Horvath T.B., and Davis K.L. Premorbid sociosexual functioning and long-term outcome in schizophrenia. Am. J. Psychiatry 146 2 (1989) 206-211
10. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., and Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 50 5 (1993) 369-376
11. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatr. Q. 71 4 (2000) 373-384
12. Marshell M., Lewis S., Lockwood A., Drake R., Jones P., and Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 62 9 (2005) 975-983
13. Perkins D.O., Gu H., Boteva K., and Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 162 10 (2005) 1785-1804
14. Rabinowitz A. method for preserving confidentiality when linking computerized registers. Am. J. Public Health 88 5 (1998) 836
15. Rabinowitz J., Reichenberg A., Weiser M., Mark M., Kaplan Z., and Davidson M. Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital. Cross-sectional analysis. Br. J. Psychiatry 177 (2000) 26-32
16. Rabinowitz J., Harvey P.D., Eerdekens M., and Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br. J. Psychiatry 189 (2006) 31-35
17. Reeb M. Construction of a questionnaire to replace a valid structured interview in the Israeli Defense Forces (in Hebrew). Megamot Behavior. Sci. Q. 16 (1968) 69-74
18. Weiser M., Kanyas K., Malaspina D., Harvey P.D., Glick I., Goetz D., Karni O., Yakir A., Turetsky N., Fennig S., Nahon D., Lerer B., and Davidson M. Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli national hospitalization registry compared with RDC diagnoses based on SADS-L. Compr. Psychiatry 46 1 (2005) 38-42
19. Wieselgren I.M., and Lindstrom L.H. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr. Scand. 93 1 (1996) 9-19 (Jan.)